Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure

Critical Care Medicine

Volumn 38, Issue SUPPL. 4, 2010, Pages

  Napolitano, Lena M ^a   Park, Pauline K ^a   Raghavendran, Krishnan ^a   Bartlett, Robert H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

ARDS; Corticosteroids; ECMO; H1N1; Hypoxemia; Influenza; Severe respiratory failure

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; DEXAMETHASONE; ILOPROST; KETOCONAZOLE; LISOFYLLINE; LUNG SURFACTANT; METHYLPREDNISOLONE; NITRIC OXIDE; OSELTAMIVIR; PROSTACYCLIN; PROSTAGLANDIN; STEROID; ZANAMIVIR;

ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; BODY POSTURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DISEASE SEVERITY; EXTRACORPOREAL OXYGENATION; FLUID BALANCE; HUMAN; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INTENSIVE CARE UNIT; LONG TERM CARE; LOW DRUG DOSE; LUNG ALVEOLUS OXYGEN TENSION; LUNG ALVEOLUS SURFACE TENSION; LUNG COMPLIANCE; MORTALITY; NONHUMAN; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS; REVIEW; SEPSIS; SUPINE POSITION; VIRUS LOAD;

EID: 77950274542     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181cc5373     Document Type: Article

References (178)

1. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994; 20:225-232
2. Napolitano LM, Park PP, Sihler KC, et al: Centers for Disease Control and Prevention (CDC). Intensive care patients with severe novel influenza A (H1N1) virus infectionMichigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58:749-752
3. Rello J, Rodriguez A, Ibanez P, et al; H1N1 Semicyuc Working Group T: Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1) in Spain. Crit Care 2009; 13:R148
4. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al; INER Working Group on Influenza: Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361: 680-689
5. Chowell G, Bertozzi SM, Colchero MA, et al: Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 61:674-679
6. Jain S, Kamimoto L, Bramley AM, et al; for the 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team: Hospitalized patients with 2009 H1N1 Influenza in the United States, April-June 2009 N Engl J Med 2009; 361:1-10
7. Kumar A, Zarychanski R, Pinto R, et al; for the Canadian Critical Care Trials Group H1N1 Collaborative: Critically ill patients with 2009 Influenza A (H1N1) infection in Canada. JAMA 2009; 302:1872-1879
8. Dominguez-Cherti G, Lapinsky SE, Macias AE, et al: Critically ill patients with 2009 Influenza A (H1N1) in Mexico. JAMA 2009; 302:1905-1906
9. Jain S, Kamimoto L, Bramley AM, et al; the 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team: Hospitalized patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-1944
10. Li G, Yilmaz M, Kojicic M, et al: Outcome of critically ill patients with influenza virus infection. J Clin Virol. 2009; 46:275-278
11. Kawachi S, Luong ST, Shigematsu M, et al: Risk parameters of fulminant acute respiratory distress syndrome and avian influenza (H5N1) infection in Vietnamese children. J Infect Dis 2009; 200:510-515
12. Erickson SE, Martin GS, Davis JL, et al; for the NIH NHLBI ARDS Network: Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009; 37: 1574-1579
13. CDC: Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season (September 22, 2009). Available at: h1n1flu/recommendations.htm. Accessed January 31, 2010
14. Kidd IM, Down J, Nastouli E, et al: H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374:1035
15. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al: Severe human influenza infections in Thailand: Oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009; 4:e6051
16. Tremblay LN, Slutsky AS: Ventilatorinduced lung injury: From the bench to the bedside. Intensive Care Med 2006; 32:24-33
17. DosSantos CC, Slutsky AS: The contribution of biophysical lung injury to the development of biotrauma. Annu Rev Physiol 2006; 68:585-618
18. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349
19. Vuuichard D, Ganter MT, Schimmer RC, et al: Hypoxia aggravates lipopolysaccharideinduced lung injury. Clin Exp Immunol 2005; 141:248-260
20. Dernaika TA, Keddissi JI, Kinasewitz GT: Update on ARDS: Beyond the low tidal volume. Am J Med Sci 2009; 337:360-367
21. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
22. Wheeler AP, Bernard GR, Thompsont BT, et al: Pulmonary artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224
23. Rosenberg AL, Dechert RE, Park PK, et al; NIH NHLBI ARDS Network: Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: A retrospective review of the ARDSnet tidal volume study cohort. J Intensive Care Med 2009; 24:35-46
24. Stewart RM, Park PK, Hunt JP, et al; NIH/ NHLBI ARDS Clinical Trials Network: Less is more: Improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. J Am Coll Surg 2009; 208:725-735
25. Martin GS, Moss M, Wheeler AP, et al: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005; 33:1681-1687
26. The ANZIC Influenza Investigators: Critical care services and 2009 H1N1 Influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-1934
27. Richter T, Bellani G, Scott Harris R, et al: Effect of prone position on regional shunt, aeration, and perfusion in experimental acute lung injury. Am J Respir Crit Care Med 2005; 172:480-487
28. Piehl MA, Brown RS: Use of extreme position changes in acute respiratory failure. Crit Care Med 1976; 4:13-14
29. Douglas WW, Rehder K, Beynen FM, et al: Improved oxygenation in patients with acute respiratory failure: The prone position. Am Rev Respir Dis 1977; 115:559-566
30. Gattinoni L, Tognoni G, Pesenti A, et al: Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001; 345:568-573
31. Gattinoni L, Vagginelli F, Carlesso E, et al: Decrease in PaCO with prone position is predictive of improved outcome in acute respiratory distress syndrome. Crit Care Med 2003; 31:2727-2733
32. Curley MA, Hibberd PL, Fineman LD, et al: Effect of prone positioning on clinical outcomes in children with acute lung injury: A randomized controlled trial. JAMA 2005; 294:229-237
33. Mancebo J, Fernandez R, Blanch L, et al: A multicenter trial of prolonged pron ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173:1233-1239
34. Fernandez R, Trenchs X, Hamburg J, et al: Prone positioning in acute respiratory distress syndrome: A multicenter randomized clinical trial. Intensive Care Med 2008; 34: 1487-1491
35. Sud S, Sud M, Friedrich JO, et al: Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. CMAJ 2008; 178:1153-1161
36. Kopterides P, Siempos II, Armaganidis A: Prone positioning in hypoxemic respiratory failure: Meta-analysis of randomized controlled trials. J Crit Care 2009; 24:89-100
37. Abroug F, Ouanes-Besbes L, Elatrous S, et al: The effect of prone positioning in acute respiratory distress syndrome or acute lung injury: A meta-analysis. Areas of uncertainty and recommendations for research. Intensive Care Med 2008; 34:1002-1011
38. Alsaghir AH, Martin CM: Effect of prone positioning in patients with acute respiratory distress syndrome: A meta-analysis. Crit Care Med 2008; 36:603-609
39. Tiruvoipati R, Bangash M, Manktelow B, et al: Efficacy of prone ventilation in adult patients with acute respiratory failure: A meta-analysis. J Crit Care 2008; 23:101-110
40. Wells DA, Gillies D, Fitzgerald DA: Positioning for acute respiratory distress in hospitalised infants and children. Cochrane Database Syst Rev 2005; 2:CD003645
41. Romero CM, Cornejo RA, Galvez LR, et al: Extended prone position ventilation in severe acute respiratory distress syndrome: A pilot feasibility study. J Crit Care 2009; 24: 81-88
42. Ignarro LI, Buga GM, Wood KS, et al: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 9265-9269
43. Palmer R, Ferrige A, Moneada S: Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526
44. Palmer R, Ashton D, Moneada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666
45. Roberts JD, Fineman JR, Morin FC, et al: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336:605-610
46. Kinsella JP, Truog WE, Walsh WF, et al: Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131:55-62
47. Goldman AP, Tasker RC, Haworth SG, et al: Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-713
48. Hoffman GM, Ross RA, Day SE, et al: Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn. Crit Care Med 1997; 25:352-359
49. Shah NS, Nakayama DK, Jacob TD, et al: Efficacy of inhaled nitric oxide in oleic acidinduced acute lung injury. Crit Care Med 1997; 25:153-158
50. Putensen C, Rasanen J, Lopez F, et al: Continuous positive pressure modulates effect of inhaled nitric oxide on the ventilationperfusion distributions in canine lung injury. Chest 1994; 106:1563-1569
51. Fratacci MD, Frostell C, Chen TY, et al: Inhaled nitric oxide: A selective pulmonary vasocilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75: 990-999
52. Berger JI, Gibson RL, Redding GJ, et al: Effect of inhaled nitric oxide during group B streptococcal sepsis in piglets. Am Rev Respir Dis 1993; 147:1080-1086
53. Shah NS, Nakayama DK, Jacob TD, et al: Efficacy of inhaled nitric oxide in a porcine model of adult respiratory distress syndrome. Arch Surg 1994; 129:158-164
54. Krause MF, Lienhart H-G, Haberstroh J, et al: Effect of inhaled nitric oxide on intrapulmonary right-to-left shunting in two rabbit models of saline lavage induced surfactant deficiency and meconium instillation. Eur J Pediatr 1998; 157:410-415
55. Dellinger RP, Zimmerman JL, Taylor RW, et al: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998; 26:15-23
56. Lundin S, Mang H, Smithies M, et al: Inhalation of nitric oxide in acute lung injury: Results of a European multicentre study. Intensive Care Med 1999; 25:911-919
57. Taylor RW, Zimmerman JL, Dellinger RP, et al: Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291:1603-1609
58. Payen D, Vallet B: 1'ARDS GdEdNd: results of the French prospective multicentric randomised double-blind placebo controlled trial on inhaled nitric oxide (NO) in ARDS. Intensive Care Med 1999; 25:S166
59. Griffiths MJD, Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353:2683-2695
60. Sokol J, Jacobs SE, Bohn D: Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003; 1:CD002787
61. Adhikari NKJ, Burns KEA, Friedrich JO, et al: Effect of nitric oxide on oxygenation and mortality in acute lung injury: Systematic review and meta-analysis. BMJ 2007; 334: 779
62. Atz AM, Wessel DL: Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307-310
63. Atz AM, Lefler AK, Fairbrother DL, et al: Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002; 124:628-629
64. 2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-1677
65. Walmrath D, Schneider T, Schermuly R, et al: Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991-996
66. Pappert D, Busch T, Gerlach H, et al: Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995; 82:1507-1511
67. VanHeerden PV, Barden A, Michalopoulos N, et al: Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117:819-827
68. Siobal M: Aerosolized prostacyclins. Respir Care 2004; 49:640-652
69. Lowson SM: Inhaled alternatives to nitric oxide. Crit Care Med 2005; 33(Suppl): S188-S195
70. 1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1743-1747
71. Lowson SM: Inhaled alternatives to nitric oxide. Anesthesiology 2002; 96:1504-1513
72. Bartlett RH, Roloff DW, Cornell RG, et al: Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study. Pediatrics 1985; 76:479-487
73. UK Collaborative ECMO Trial Group: UK collaborative randomized trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348:75-82
74. Keckler SJ, Laituri CA, Ostlie DJ, et al: A review of venovenous and venoarterial extracorporeal membrane oxygenation in neonates and children. Eur J Pediatr Surg 2009; 2009 September 10 [Epub ahead of print]
75. Extracorporeal Life Support Organization: Annual ECMO Registry Report. July 2003
76. Rich PB, Awad SS, Kolla S, et al: An approach to the treatment of severe adult respiratory failure. J Crit Care 1998; 13:26-36
77. Hemmila MR, Rowe SA, Boules TN, et al: Extracorporeal life support for severe acute respiratory distress syndrome in adults. Ann Surg 2004; 240:595-607
78. Brogan TV, Thiagarajan RR, Rycus PT, et al: Extracorporeal membrane oxygenation in adults with severe respiratory failure: A multicenter database. Intensive Care Med 2009; 35:2105-2114
79. Santambrogio L, Nosotti M, Palleschi A, et al: Use of venovenous extracorporeal membrane oxygenation as a bridge to urgent lung transplantation in a case of acute respiratory failure. Transplant Proc 2009; 41: 1345-1346
80. Linden VB, Lidegran MK, Frisen G, et al: ECMO in ARDS: A long-term followup study regarding pulmonary morphology and function and health-related quality of life. Acta Anaesthesiol Scand 2009; 53:489-495
81. Peek GJ, Mugford M, Tiruvoipati R, et al; for the CESAR trial collaboration: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomized controlled trial. Lancet 2009; 374:1351-1363
82. The ANZIC Influenza Investigators: Critical care services and 2009 H1N1 Influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1-10
83. The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators: Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009; 302:1888-1895
84. Heulitt MJ, Taylor BJ, Faulkner SC, et al: Inter-hospital transport of neonatal patients on extracorporeal membrane oxygenation: Mobile ECMO. Pediatrics 1995; 95:562-566
85. Reng M, Philipp A, Kaiser M, et al: Pumpless extracorporeal lung assist and adult respiratory distress syndrome. Lancet 2000; 356: 219-220
86. Ruettimann U, Ummenhofer W, Rueter F, et al: Management of acute respiratory distress syndrome using pumpless extracorporeal lung assist. Can J Anaesth 2006; 53: 101-105
87. Bein T, Scherer MN, Philipp A, et al: Pumpless extracorporeal lung assist (pECLA) in patients with acute respiratory distress syndrome and severe brain injury. J Trauma 2005; 58:1294-1297
88. Zimmerman M, Bein T, Philipp A, et al: Interhospital transportation of patients with severe lung failure on pumpless extracorporeal lung assist. Br J Anaesth 2006; 96:63-66
89. Terragni PP, Del Sorbo L, Mascia L, et al: Tidal volume lower than 6m1/kg enhances lung protection. Anesthesiology 2009; 111: 826-835
90. Adhikari N, Burns KE, Meade MO: Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: Systematic review and meta-analysis. Treat Respir Med 2004; 3:307-328
91. Raghavendran K, Pryhuber GS, Chess PR, et al: Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem 2008; 15:1911-1924
92. ARDS Network: Ketoconazole for the early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2000; 283: 1995-2002
93. ARDS Network: Randomized, placebocontrolled trial of lisofylline for the early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1-6
94. Adhikari N, Burns KE, Meade MO: Phmarcologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004; 4:CD004477
95. Bone RC, Fisher CJ Jr, Clemmer TP, et al: Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987; 92: 1032-1036
96. Luce JM, Montgomery AB, Marks JD, et al: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138:62-68
97. Bernard GR, Luce JM, Sprung CL, et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317:1565-1570
98. Weigelt JA, Norcross JF, Borman KR, et al: Early steroid therapy for respiratory failure. Arch Surg 1985; 120:536-540
99. Ashbaugh DG, Maier RV: Idiopathic pulmonary fibrosis in adult respiratory distress syndrome: Diagnosis and treatment. Arch Surg 1985; 120:530-535
100. Biffl WL, Moore FA, Moore EE, et al: Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995; 170:591-596
101. Hooper RG, Kearl RA: Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990; 97:138-143
102. Braude S, Haslam P, Hughes D, et al: Chronic adult respiratory distress syndrome-a role for corticosteroids? Crit Care Med 1992; 20:1187-1189
103. Keel JB, Hauser M, Stocker R, et al: Established acute respiratory distress syndrome: Benefit of corticosteroid rescue therapy. Respiration 1998; 65:258-264
104. Meduri GU, Belenchia JM, Estes RJ, et al: Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 1991; 100:943-952
105. Meduri GU, Headley AS, Golden E, et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998; 280:159-165
106. Steinberg KP, Hudson LD, Goodman RB; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684
107. Hough CL, Steinberg KP, Taylor Thompson B, et al: Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009; 35:63-68
108. Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954-963
109. Meduri GU, Marik PE, Chrousos GP, et al: Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34:61-69
110. Meduri GU, Annane D, Chrousos GP, et al: Activation and regulation of systemic inflammation in ARDS: Rationale for prolonged glucocorticoid therapy. Chest 2009; 136:1631-1643
111. Tang BMP, Craig JC, Eslick GD, et al: Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. Crit Care Med 2009; 37:1594-1603
112. Ferguson ND: ACP Journal Club. Review: Low-dose corticosteroids improve outcomes in acute lung injury and the acute respiratory distress syndrome. Ann Intern Med 2009; 151JC3-JC12
113. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327
114. Marik PE, Pastores SM, Annane D, et al: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937-1949
115. Xu T, Qiao J, Zhao L, et al: Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. Eur Respir J 2009; 33:852-860
116. Wang XO, Zhou S, Zhou Y, et al: Low-dose dexamethasone alleviates lipopolysaccharide-induced acute lung injury in rats and upregulates pulmonary glucocorticoid receptors. Respirology 2008; 13:772-780
117. Aberdein J, Singer M: Clinical review: A systematic review of corticosteroid use in infections. Crit Care 2006; 10:203
118. Gagnon S, Boota AM, Fischl MA, et al: Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990; 323:1444-1450
119. Gregory PB, Knauer CM, Kempson RL, et al: Steroid therapy in severe viral hepatitis. A double-blind randomized trial of methylprednisolone versus placebo. N Engl J Med 1976; 294:681-687
120. Henry SD, Metselaar JH, Van Dijck J, et al: Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann NY Acad Sci 2007; 1110:439-447
121. Kidd IM, Down J, Nastouli E, et al: H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374:1036
122. Carter MJ: A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 2007; 56(Pt 7): 875-883
123. Hui DS: Influenza A/H5N1 infection: Other treatment options and issues. Respirology 2008; 13(Suppl 1):S22-S26
124. Writing committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus: Update on Avian Influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-273
125. Hien ND, Ha NH, Van NT, et al: Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005. Emerg Infect Dis 2009; 15: 19-23
126. Stevens TP, Blennow M, Soll RF: Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS. Cochrane Database Syst Rev 2002; 2:CD003063
127. Sinha SK, Lacaze-Masmonteil T, Valls I, Soler A, et al: A multicenter, randomized, controlled trial of lucinanctant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115:1030-1038
128. Spragg RG, Lewis JF, Walmrath HD, et al: Effect of recombinant surfactant protein Cbased surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 31: 884-892
129. Baudouin SV: Exogenous surfactant replacement in ARDS-one day, someday, or never? N Engl J Med 2004; 351:853-855
130. Petty T, Reiss O, Paul G, et al: Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis 1977; 115:531-536
131. Hallman M, Spragg R, Harrell JH, et al: Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70:673-683
132. Seeger W, Pison U, Buchhorn R, et al: Surfactant abnormalities and adult respiratory failure. Lung 1999; 168(Suppl):891-902
133. Pison U, Seeger W, Buchhorn R, et al: Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989; 140:1033-1039
134. Gregory TJ, Longmore WJ, Moxley MA, et al: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981
135. Veldhuizen R, McCaig L, Akino T, et al: Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:1867-1871
136. Griese M: Pulmonary surfactant in health and human lung diseases: State of the art. Eur Respir J 1999; 13:1455-1476
137. Günther A, Siebert C, Schmidt R, et al: Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153:176-184
138. McCormack FX: New concepts in collectinmediated host defense at the air-liquid interface of the lung. Respirology 2006; (Suppl. 11):S7-S10
139. McCormack FX, Whitsett JA: The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung J Clin Invest 2002; 109:707-712
140. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev 1997; 77:931-962
141. Crouch E, Wright JR: Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001; 63:521-554
142. Schwab U, Rohde KH, Wang Z, et al: Transcriptional responses of Mycobacterium tuberculosis to lung surfactant. Microb Pathog 2009; 46:185-193
143. El Shahed AI, Dargaville P, Ohlsson A, et al: Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrrane Database Syst Rev 2007; 18: CD002054
144. Khammash H, Perlman M, Wojtulewicz J, et al: Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92:135-139
145. Findlay RD, Taeusch HW, Walther FJ: Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97: 48-52
146. Stevens TP, Harrington EW, Blennow M, et al: Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007; 4:CD003063
147. Willson DF, Chess PR, Notter RH: Surfactant for pediatric acute lung injury. Pediatr Clin North Am 2008; 55:545-575
148. Playfor SD, Nootigattu VK: Exogenous surfactant in pediatric acute lung injury and acute respiratory distress syndrome. Curr Drug Saf 2006; 1:159-168
149. Willson DF, Zaritsky A, Bauman LA, et al: Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network. Crit Care Med 1999; 27:188-195
150. Willson DF, Jiao JH, Bauman LA, et al: Calf's lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 1996; 24:1316-1322
151. Willson DF, Thomas NJ, Markovitz BP, et al: Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293:470-476
152. Walmrath D, Grimminger F, Pappert D, et al: Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: Impact on gas exchange and haemodynamics. Eur Respir J 2002; 9:805-810
153. Walmrath D, Gunther A, Ghofrani HA, et al: Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154:57-62
154. Gunther A, Schmidt R, Harodt J, et al: Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: Impact on biophysical and biochemical surfactant properties. Eur Respir J 2002; 10:797-804
155. Spragg R: Surfactant therapy in acute respiratory distress syndrome. Biol Neonate 1998; 74(Suppl):15-20
156. Spragg R, Gilliard N, Richman P, et al: Acute effects of single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195-202
157. Anzueto A, Baughman RP, Guntupalli KK, et al: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334:1417-1421
158. Gregory TJ, Steinberg KP, Spragg R, et al: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309-1315
159. Notter RH, Wang Z, Egan EA, et al: Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002; 114:21-34
160. Wang Z, Baatz JE, Holm BA, et al: Contentdependent activity of lung surfactant protein B in mixtures with lipids. Am J Physiol Lung Cell Mol Physiol 2002; 283: L897-L906
161. Spragg RG, Lewis JF, Wurst W, et al: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562-1566
162. Taut FJH, Rippin G, Schenk P, et al: A search for subgroups of patients with the acute respiratory distress syndrome who may benefit from surfactant replacement therapy: A pooled analysis of five studies with rSP-C Surfactant (Venticute). Chest 2008; 134:724-732
163. Walther FJ, Waring AJ, Hernandez-Juviel JM, et al: Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/ peptide lung surfactant. PLoS ONE 2007; 2:e1039
164. Wang Z, Chang Y, Schwan AL, et al: Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lung. Am J Respir Cell Mol Biol 2007; 37: 387-394
165. Notter RH, Wang Z, Wang Z, et al: Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants. Bioorg Med Chem Lett 2007; 17:113-117
166. Kwatia MA, Doyle CB, Cho W, et al: Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis. J Allergy Clin Immuno 2007; 119:838-847
167. Kesecioglu J, Beale R, Stewart TE, et al: Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009; 180:989-994
168. Schultz MJ, Haitsma JJ, Zhang H, et al: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-A review. Crit Care Med 2006; 34:871-877
169. Matthay MA, Ware LB: Plasma protein C levels in patients with acute lung injury: Prognostic significance. Crit Care Med 2004; 32(Suppl 5):S229-S232
170. Waerhaug K, Kuzkov W, Kuklin VN, et al: Inhaled aerosolised recombinant human activated protein C ameliorates endotoxininduced lung injury in anaesthetised sheep. Crit Care 2009; 13:R51
171. Waerhaug K, Kuklin VN, Kirov MY, et al: Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 2008; 12:R104
172. Waerhaug K, Kirov MY, Kuzkov VV, et al: Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep. Crit Care 2008; 12:R146
173. Liu KD, Levitt J, Zhuo H, et al: Randomized clinical trial of activated protein c for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618-623
174. Fedson DS: Clinical and experimental studies of the molecular pathophysiology of influenza. In: The Threat of Pandemic Influenza: Are We Ready? Knobler SL, Mack A, Mahmoud A, et al (Eds). Washington, DC, The National Academies Press, 2005, pp 194-196
175. Fedson DS: Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43: 199-205
176. Terblanche M, Smith TS, Adhikari NK: Statins, bugs and prophylaxis: Intriguing possibilities. Crit Care 2006; 10:168
177. Liu Z, Guo Z, Wang G, et al: Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 2009; 38:215-223
178. Violette AK, Thomas J, Lowell M, et al: ARDS algorithm for critical care transport of severe ARDS patients for ECMO evaluation. Am J Respir Crit Care Med 2009; 179: A4655